Abstract: Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. pylori in a subject infected by H. pylori, the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Abstract: Disclosed herein are 3-azabicyclo[3.1.0]hexan-6-amine compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
August 16, 2022
Assignee:
Vanderbilt University
Inventors:
Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers, Aaron M. Bender
Abstract: Disclosed are a compound represented by Chemical Formula 1, an optical filter, an image sensor, a camera module, and an electronic device. In Chemical Formula 1, R1 to R27 and n are the same as defined in the detailed description.
Type:
Grant
Filed:
November 4, 2019
Date of Patent:
August 9, 2022
Assignee:
Samsung Electronics Co., Ltd.
Inventors:
Yong Joo Lee, Changki Kim, Jae Jun Lee, Mi Jeong Kim
Abstract: A fused tricyclic compound, an optical isomer, cis and trans isomers or an agromedically acceptable salt thereof, and insecticidal use thereof in agroforestry. A pyrazole-ring-contained fused heterocyclic compound, an agricultural composition, and a method of using the agricultural composition are also provided.
Abstract: The present invention relates to quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), the preparation thereof and uses thereof. Formula (I).
Type:
Grant
Filed:
March 29, 2018
Date of Patent:
August 2, 2022
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Stanley Watowich, Harshini Neelakantan, Hua-Yu Wang, Stanton Mchardy
Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.
Abstract: To provide a method that can efficiently produce 2,5-bis(aminomethyl)tetrahydrofuran. The method for producing 2,5-bis(aminomethyl)tetrahydrofuran, the method including subjecting 2,5-bis(aminomethyl)furan to a reaction with hydrogen source by using a hydrogenation catalyst to obtain 2,5-bis(aminomethyl)tetrahydrofuran.
Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
July 26, 2022
Assignee:
Nimbus Lakshmi, Inc.
Inventors:
Jeremy Robert Greenwood, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
Abstract: Novel methods for treating cancer include: administering a glucocorticoid receptor modulator (GRM) to a patient, and determining whether or not the expression level of a gene is decreased in comparison with baseline levels of the gene measured in the patient prior to the GRM administration, thereby identifying a patient as being likely to benefit from cancer chemotherapy in conjunction with GRM administration where the expression level of a gene following GRM administration is decreased in comparison with corresponding gene baseline levels; and administering to said identified patient a combination of a GRM and cancer chemotherapy, whereby the cancer is treated in the patient. The GRM may be selected from relacorilant, CORT125281, CORT122928, and CORT113176. The cancer chemotherapy agent may be a taxane. The gene expression level measured may be selected from 50 identified genes, and may be selected from COX2, DUSP1, GSK3b, MCL-1, PIK3CG, RGS-2, SGK1, and STAT3.
Type:
Grant
Filed:
December 18, 2019
Date of Patent:
July 19, 2022
Assignee:
Corcept Therapeutics Incorporated
Inventors:
Andrew Greenstein, Stacie Shepherd, Andreas G. Moraitis
Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
Type:
Grant
Filed:
July 4, 2018
Date of Patent:
June 28, 2022
Assignee:
INFLAZOME LIMITED
Inventors:
Matthew Cooper, David Miller, Angus Macleod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
Abstract: The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I), and pharmaceutical compositions thereof, are antagonists of toll-like receptors such as TLR7, TLR8, and/or TLR9. In certain embodiments, compounds of the invention are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
Type:
Grant
Filed:
November 9, 2017
Date of Patent:
June 28, 2022
Assignee:
DYNAVAX TECHNOLOGIES CORPORATION
Inventors:
Albert Frederick Candia, III, Richard Thomas Beresis, Robert L. Coffman
Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
Type:
Grant
Filed:
July 17, 2020
Date of Patent:
June 14, 2022
Assignee:
PharmAkea, Inc.
Inventors:
Martin W. Rowbottom, John Howard Hutchinson, David Lonergan
Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compound and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
June 7, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
Liping Zhang, Emily Charlotte Cherney, James Aaron Balog, Xiao Zhu
Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).
Type:
Grant
Filed:
September 7, 2017
Date of Patent:
May 24, 2022
Assignee:
FGH BIOTECH, INC.
Inventors:
Motonari Uesugi, John Kincaid, Joel Huff
Abstract: Crystalline N-methyl tryptamine derivatives, compositions containing those crystalline forms and their methods of use are disclosed. The crystalline N-methyl tryptamine derivatives according to the invention include crystalline N-methyl-N-propyltryptamine (MPT), crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) and crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate).
Abstract: The present invention discloses a nitrogen-containing heterocyclic substituted benzoxazine oxazolidinone compound, a preparation method and use thereof in the manufacture of a medicament for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I) and stereoisomer thereof, pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compounds of the present invention, use thereof, a method for preparing the compound, in which X1, X2, R1 and R2 are described in the specification.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
May 17, 2022
Assignee:
Institute of Materia Medica, Chinese Academy of Medical Sciences
Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
Type:
Grant
Filed:
July 6, 2017
Date of Patent:
May 3, 2022
Assignee:
Cyclerion Therapeutics, Inc.
Inventors:
Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston
Abstract: The disclosed and/or claimed inventive concept(s) provides a complex of at least one halogen and a compound comprising at least one ether, thioether, and/or imine moiety and at least two lactam moieties. The disclosed and/or claimed inventive concept(s) further provides compositions comprising the complexes and applications thereof in various industrial areas including personal care, home care, pharmaceuticals, antimicrobials, disinfectants, biocides, germicides, and coatings.
Type:
Grant
Filed:
July 26, 2018
Date of Patent:
May 3, 2022
Assignee:
ISP INVESTMENTS LLC
Inventors:
Osama M. Musa, Melissa J. Goodwin, Benjamin W. Steed, Jonathan W. Steed